Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Discussion: It is reported that a differential genetic barrier was found for V106M, V108I, P225H in different HIV-1 subtypes for NNRTI resistance-related substitutions.
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Figure: Major NNRTI-associated DRMs (HIVDB score >=60) included: L100I, K101P, K103N/S, V106A/M, Y181C/I/V, Y188L/H/C, G190A/S/E/Q, and M230L.
Discussion: These six DRMs include two NRTI-associated DRMs (K65R and M184V) and four NNRTI-associated DRMs (K103N, V106M, Y181C, and G190A).
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
PMID: 23934770
2014
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Sixteen mutations at 10 positions were significantly associated with the greatest contribution to reduced phenotypic susceptibility (>=10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine ( PMID: 24439027
2014
Journal of the International AIDS Society
Abstract: Non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs were present in all (100%) children whose viruses harboured DRMs: K103N in 43%; Y181C, K101E and V106M each in 29%; and Y188L in 14%.
Result: NNRTI resistance mutations were present in all (100%) children whose viruses harboured DRM: K103N in 43%, Y181C, K101E and V106M each in 29%; and Y188L in 14%.
Table: V106M
Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.
Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.
PMID: 24740080
2014
Journal of clinical microbiology
Abstract: Nonnucleoside reverse transcriptase inhibitor (K103N, V106M, Y181C, and G190A) and lamivudine (M184V) resistance mutations were quantified in blood-derived plasma RNA and cell DNA specimens by OLA and 454 pyrosequencing.
E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.
Introduction: For example, the V106M RT substitution, which confers resistance to the NNRTIs efavirenz (EFV) and nevirapine (NVP), has been reported more frequently in subtype C viruses than in subtype B.
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
Result: The most common NNRTI mutation in this group was K103N (n = 152, 57.4%) followed by V106M (n = 105, 39.6%), P225H (n = 42, 15.8%) and V179D (n = 29, 10.9%, Figure 1).
HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania.
HIV mutation literature information.
PMID: 
2015
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT